Disease Domain | Count |
---|---|
Immune System Diseases | 2 |
Top 5 Drug Type | Count |
---|---|
Exosomes | 4 |
Top 5 Target | Count |
---|---|
IL-31R(Interleukin 31 receptor) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IL-31R inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date18 Apr 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
BRE-AD01 ( IL-31R ) | Dermatitis, Atopic More | Phase 1 |
BxC-I17e | Dermatitis, Atopic More | Phase 1 |
exosome based therapeutic (Brexogen) | Nonalcoholic Steatohepatitis More | Preclinical |
BRE-MI01 | Myocardial Infarction More | Discovery |
BRE-RF01 | Kidney Diseases More | Discontinued |